How has been the historical performance of Trident Texofab?

Answer:The historical performance of Trident Texofab shows a steady increase in net sales and total operating income over the years, with net sales rising from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25. The total operating income followed a similar trend, reaching 122.06 Cr in Mar'25 from 49.93 Cr in Mar'21. Operating profit (PBDIT) also saw fluctuations, peaking at 8.78 Cr in Mar'25, although it was lower than the previous year's 8.21 Cr. Profit before tax increased to 2.58 Cr in Mar'25, up from 1.17 Cr in Mar'24, while profit after tax rose to 2.51 Cr from 1.08 Cr in the same period. The company's total assets grew significantly from 55.68 Cr in Mar'20 to 100.58 Cr in Mar'25, reflecting a robust expansion strategy. However, total debt decreased from 36.96 Cr in Mar'24 to 26.50 Cr in Mar'25, indicating improved financial health. The earnings per share (EPS) increased to 1.85 in Mar'25 from 1.07 in Mar'24, showcasing enhanced profitability per share. Breakdown: Trident Texofab's financial performance demonstrates a consistent upward trajectory in net sales, which increased from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, indicating strong revenue growth. Total operating income mirrored this growth, reaching 122.06 Cr in Mar'25. Operating profit (PBDIT) fluctuated, peaking at 8.78 Cr in Mar'25, while profit before tax rose to 2.58 Cr, reflecting improved operational efficiency. The company's total assets expanded significantly to 100.58 Cr in Mar'25, up from 55.68 Cr in Mar'20, while total debt decreased, suggesting a strengthening balance sheet. Earnings per share also improved, reaching 1.85 in Mar'25, highlighting the company's ability to generate profit for its shareholders. Overall, Trident Texofab's financial metrics indicate a positive growth trend and enhanced profitability over the years.